AACR19: ipilimumab, nivolumab combination demonstrates efficacy in high-grade neuroendocrine carcinoma

Written by Zoe Campbell, Future Science Group

Results from the DART Phase II clinical trial indicate that a therapeutic combination of the anti-CTLA-4 immunotherapeutic, ipilimumab (Yervoy®), and the anti-PD-1 immunotherapeutic, nivolumab (Opdivo®), may be beneficial to patients with rare, high-grade neuroendocrine carcinoma. The Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) trial aims to evaluate the efficacy of ipilimumab (1 mg/kg every 6 weeks) in combination with nivolumab (240 mg every 2 weeks) in patients with rare tumors. At the AACR Annual Meeting 2019 (29 March – 3 April 2019; GA, USA), researchers presented a summary of their study, which shows patients with rare, high-grade neuroendocrine...

To view this content, please register now for access

It's completely free